Related Experiment Video

Updated: Aug 17, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by

Michael T Spiotto1, Hans Schreiber

  • 1Department of Pathology, The University of Chicago, Chicago, IL 60637, USA.

Cancer Immunity
|June 7, 2005
PubMed

Insights

Antigen-specific T cells can eliminate antigen-loss variants (ALVs) by destroying surrounding stromal cells. However, ALVs escape if stromal antigen cross-presentation is insufficient, highlighting the importance of stroma in tumor rejection.

Area of Science:

  • Immunology
  • Cancer Biology
  • Tumor Microenvironment

Background:

  • Tumors exhibit cellular heterogeneity, including antigen-loss variants (ALVs) that evade T cell-mediated killing.
  • Cytotoxic T lymphocytes (CTLs) target cancer cells expressing specific antigens, but ALVs lack these antigens, enabling immune escape.

Purpose of the Study:

  • To investigate whether antigen-specific T cells can eliminate ALVs.
  • To determine the role of stromal antigen cross-presentation in the bystander killing of ALVs.

Main Methods:

  • Utilized a model gp33 antigen (KAVYNFATM) to study antigen presentation and cross-presentation by stromal cells.
  • Assessed the susceptibility of ALVs to CTL-mediated killing under varying conditions of antigen expression and stromal integrity.

Main Results:

  • Antigen-specific T cells eliminated ALVs when the parental tumor cells expressed sufficient gp33 antigen for cross-presentation by stromal cells.
  • ALVs were spared from bystander killing when stromal cells lacked appropriate MHC or when antigen levels were too low for effective cross-presentation.
  • Rapid destruction of both stroma and parental cancer cells was observed, potentially preventing variant escape.

Conclusions:

  • Stromal cross-presentation of tumor antigens is crucial for the bystander elimination of ALVs by antigen-specific T cells.
  • Effective tumor rejection, including the eradication of ALVs, may depend on the coordinated destruction of the tumor and its associated stroma.
  • Understanding these mechanisms is vital for developing cancer immunotherapies that overcome immune evasion by antigen loss.

More Related Videos

Heteromulticellular Stromal Cells in Scaffold-free 3D Cultures of Epithelial Cancer Cells to Drive Invasion09:18

Heteromulticellular Stromal Cells in Scaffold-free 3D Cultures of Epithelial Cancer Cells to Drive Invasion

Published on: April 4, 2025

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...